Since 1964, the US Centers for Disease Control and Prevention (CDC) had regularly reviewed the evidence on the safety and efficacy of fall vaccines and gave the results to its Advisory Committee on ...

FDA approved zopapogene imadenovec, the first therapy for recurrent respiratory papillomatosis, providing an option beyond ...

The American Academy of Pediatrics is splitting from the federal government in its recommendations on which children should ...

The test is now authorized for use with anterior nasal swab samples in addition to the previously authorized throat and nasopharyngeal samples.

SHELTON, CONNECTICUT / / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...

Research and Development Expenses-- $4,700,000 compared to $5,600,000 during the prior year comparable period. Kodiak PCR ...

Key Points GAAP revenue jumped 413% year over year to $11.8 million in Q2 2025, but fell far short of analyst estimates, with GAAP revenue of $11.8 million missing the consensus of $23.2 million by 49 ...

Invivyd ( (IVVD) ) just unveiled an update. On August 14, 2025, Invivyd announced its alignment with the U.S. FDA on a rapid pathway to full approval for its monoclonal antibody candidate VYD2311, ...

WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided recent business highlights.